Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tislelizumab in Neoadjuvant HER2-low Breast Cancer
NCT05861635Phase 4Recruiting
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 4 trial of disitamab vedotin in breast cancer. Started Feb 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05861635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861635.